For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS) have grown remarkably where DMTs been shown to reduce risk of MS relapses. patients are advised begin treatment with a DMT shortly after diagnosis limit possibility disease progression over time. While radiologically isolated syndrome do not require pharmacologic treatment, high-risk clinically start DMTs...

Fingolimod was recently approved for use in the United States after two phase III trials confirmed its effectiveness in reducing disease activity in relapsing-remitting multiple sclerosis. These positive results, coupled with the important fact that this is the first oral disease-modifying therapy, has lead to considerable enthusiasm amongst physicians and patients. However, fingolimod is assoc...